Navigation Links
Oncothyreon's PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
Date:11/16/2009

SEATTLE, Nov. 16 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (the "Company") today announced that the Company's product candidate PX-866, a PI-3 kinase inhibitor, has been selected by Windhover Information, Inc., as one of the Top 10 most promising oncology projects in development that is available for partnering.

The selection was made by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology and medical device industries. As a selected company, Oncothyreon will present data on PX-866 at Windhover's Therapeutic Area Partnerships conference on November 17-19, 2009, in Boston, MA.

PX-866 is an inhibitor of the PI-3-kinase/PTEN/AKT pathway, an important survival signaling pathway that is activated in many types of human cancer. Oncothyreon is currently conducting a Phase 1 trial of PX-866 in patients with advanced metastatic cancer. Based upon the results seen in this trial to date, including the preliminary data presented at the American Society of Oncology Annual Meeting (ASCO) earlier this year, Oncothyreon has made the decision to move PX-866 into Phase 2 clinical development in the first half of 2010. The Phase 2 development program is currently expected to include two or more trials of PX-866 in combination with chemotherapy or other targeted agents and as a single agent.

"Preliminary results from our ongoing trial of PX-866 have demonstrated that the activity of the target, PI-3 kinase, can be down-regulated at doses well below the maximally tolerated dose identified in the intermittent dosing arm," said Robert L. Kirkman, M.D., President and Chief Executive Officer of Oncothyreon. "As reported at ASCO, we have also had several patients with prolonged stable disease
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
2. Oncothyreon files investigational new drug application for PX-866 oncology compound
3. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
4. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
5. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
6. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
7. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
8. ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase
9. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
10. CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform
11. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues  ("BioLife" ... its 2015 Annual Meeting of Stockholders on May 4, ... date for the Annual Meeting represents a change of ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... series is designed to introduce cutting edge ... users and partners of platform upgrades. This ... benefits; empowering users in their quest to ... tools. , According to SoundConnect’s Marketing Manager, ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. George ... Society for Reproductive Medicine (ASRM), a leading professional organization ... In his new role as treasurer, Dr. Hill ... will have a voice in furthering the mission of ... since 1984 when he joined while conducting fellowship training ...
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... Quarter Highlights: - Revenues of $88.4 million, up 14% from the, ... of, 47% over last year,s third quarter - Operating cash flow ... full year 2008 ... and earnings guidance, COLUMBIA, Md., Sept. 4 Martek Biosciences,Corporation (Nasdaq: ...
... COLLINS, Colo., Sept. 4 InVitria,( ... of animal free,products that enhance productivity, ... companies,in the biopharmaceutical, cell culture, life ... Sponsorship of Cambridge Healthtech,Institute,s 4th Annual ...
... and The University of North Carolina-Chapel Hill ... Drug Safety Sciences, RESEARCH TRIANGLE PARK, N.C., Sept. ... University of North Carolina at,Chapel Hill announced they are ... be led by Dr. Paul Watkins, one of the ...
Cached Biology Technology:Martek Announces Third Quarter 2008 Financial Results 2Martek Announces Third Quarter 2008 Financial Results 3Martek Announces Third Quarter 2008 Financial Results 4Martek Announces Third Quarter 2008 Financial Results 5Martek Announces Third Quarter 2008 Financial Results 6Martek Announces Third Quarter 2008 Financial Results 7Martek Announces Third Quarter 2008 Financial Results 8Martek Announces Third Quarter 2008 Financial Results 9Martek Announces Third Quarter 2008 Financial Results 10InVitria Sponsors Cambridge Healthtech's Optimizing Cell Culture Development Conference 2New Hamner-UNC Center for Drug Safety Sciences 2New Hamner-UNC Center for Drug Safety Sciences 3
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
(Date:12/3/2014)... As part of our commitment to offering ... to announce the release of a new reader that ... workforce data that they need. The Atlas ... existing readers. Many such devices have serious shortcomings when ... Older models force users to navigate numerous complicated steps ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2
... North Sea, strong currents, a large number of river estuaries ... the Baltic represents an inland sea with highly different water ... also influence the fate of fish stocks has now been ... Centre for Ocean Research Kiel and the National Institute of ...
... The zebrafish, a tropical freshwater fish similar to a ... well established as a key tool for researchers studying ... determine how individual neurons develop, mature and support basic ... the University of Missouri say that learning about neuronal ...
... Ill. The Cache River Basin, which once ... counties, has changed substantively since the ancient Ohio River ... soils and productive farmlands; deep sand and gravel deposits; ... and diverse natural habitats in Illinois and the nation. ...
Cached Biology News:Stratification determines the fate of fish stocks in the Baltic Sea 2Research of zebrafish neurons may lead to understanding of birth defects like spina bifida 2Agricultural productivity loss as a result of soil and crop damage from flooding 2Agricultural productivity loss as a result of soil and crop damage from flooding 3
ANTI NO-TRYPTOPHAN CONJUGATE...
... Background/Kan Cloning Kit includes the ... for selection in E. coli. ... selection to eliminate high background. ... the reagents you need for ...
GOAT ANTI SLI...
Protein Phosphorylation...
Biology Products: